Atomoxetine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Schizophrenia

Conditions

Schizophrenia

Trial Timeline

Jan 1, 2005 → Jun 1, 2007

NCT ID

NCT00488163

About Atomoxetine

Atomoxetine is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00488163. Target conditions include Schizophrenia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01177943	Phase 1	Completed	Aug 1, 2010	Oct 1, 2010	Attention Deficit Hyperactivity Disorder
NCT00969618	Phase 3	Completed	Nov 1, 2009	Jan 1, 2012	Attention Deficit Hyperactivity Disorder
NCT00760747	Approved	Completed	Sep 1, 2008	Sep 1, 2010	Attention Deficit Hyperactivity Disorder
NCT00687609	Approved	Terminated	Sep 1, 2008	Jun 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00636818	Phase 2	Completed	Mar 1, 2008	Oct 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00530335	Phase 2	Completed	Sep 1, 2007	Apr 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00471354	Approved	Completed	Apr 1, 2007	Nov 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00918567	Approved	Completed	Jan 1, 2007	Sep 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00299234	Approved	Terminated	Jun 1, 2006	Dec 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00320528	Phase 3	Completed	Apr 1, 2006	Oct 1, 2008	Attention Deficit Disorder With Hyperactivity
NCT00252278	Approved	UNKNOWN	Nov 1, 2005	—	Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00255138	Phase 3	Withdrawn	Nov 1, 2005	—	Cancer
NCT00953862	Pre-clinical	Completed	Jul 1, 2005	Apr 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00191633	Approved	Completed	Apr 1, 2005	Jun 1, 2006	Attention-Deficit/Hyperactivity Disorder
NCT00286949	Pre-clinical	Completed	Jan 6, 2005	Jun 30, 2008	Parkinson's Disease
NCT00488163	Approved	Completed	Jan 1, 2005	Jun 1, 2007	Schizophrenia
NCT00191737	Phase 3	Completed	Oct 1, 2004	Feb 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191516	Phase 3	Completed	Oct 1, 2004	Feb 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191880	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Attention Deficit Hyperactivity Disorder
NCT00191035	Approved	Completed	Mar 1, 2004	Nov 1, 2006	Attention-Deficit/Hyperactivity Disorder

Competing Products

20 competing products in Schizophrenia

See all competitors

Product	Company	Stage	Hype Score
antipsychotic dose increase	Eli Lilly	Pre-clinical	23
Olanzapine + Placebo	Eli Lilly	Phase 3	77
Olanzapine + Aripiprazole	Eli Lilly	Approved	85
olanzapine therapy	Eli Lilly	Approved	85
olanzapine-RAIM + placebo	Eli Lilly	Phase 2	52
Clozapine + Olanzapine	Eli Lilly	Approved	85
Risperidone + Placebo + LY2140023	Eli Lilly	Phase 2	52
Olanzapine + olanzapine + risperidone	Eli Lilly	Approved	85
Zotepine + Risperidone	Astellas Pharma	Approved	85
ASP4345 + Matching Placebo	Astellas Pharma	Phase 1	33
ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidone	Astellas Pharma	Phase 2	52
ASP6981 + Placebo	Astellas Pharma	Phase 1	33
SAPHRIS + Asenapine	Sun Pharmaceutical	Phase 1	33
Torrent's Quetiapine Fumarate Tablets	Torrent Pharmaceuticals	Phase 1	33
Olanzapine Hydrochloride	Eli Lilly	Phase 1/2	41
Rapid-Acting Intramuscular Olanzapine + Placebo	Eli Lilly	Phase 3	77
Pomaglumetad methionil	Eli Lilly	Phase 3	77
Olanzapine	Eli Lilly	Approved	85
Intramuscular Olanzapine Depot + Placebo	Eli Lilly	Phase 3	77
olanzapine + atomoxetine + placebo	Eli Lilly	Phase 1/2	41

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved